• Fulvestrant (ICI 182,780): Mechanistic Precision for Transla

  2026-07-03

  This thought-leadership article provides translational researchers with a mechanistic and strategic roadmap for leveraging Fulvestrant (ICI 182,780) in ER-positive breast cancer research. By integrating the latest evidence on estrogen receptor antagonism, apoptosis pathways, MDM2 protein degradation, and the immunological landscape, the article moves beyond conventional product overviews to offer workflow-driven guidance, protocol clarity, and a future-looking perspective grounded in both preclinical and clinical domains.

• Decoding mRNA Delivery: Structural Insights with EZ Cap™ Cy5

  2026-07-03

  Explore how EZ Cap™ Cy5 EGFP mRNA (5-moUTP) advances dual-fluorescence mRNA delivery and translation assays. This article reveals unique structural and assay innovations, providing researchers with actionable strategies beyond conventional approaches.

• Network Meta-Analysis: Azilsartan Medoxomil in Hypertension

  2026-07-02

  A recent systematic review and network meta-analysis establishes azilsartan medoxomil (TAK 491) as the most effective antihypertensive among major agents for mild-to-moderate hypertension. By synthesizing data from 21 randomized trials, the study provides robust comparative evidence that supports the clinical and preclinical prioritization of this agent for blood pressure regulation studies.

• Gut-Brain Cholinergic Pathways in Microbiota-Mediated Seizur

  2026-07-02

  Jia et al. reveal that Bacteroides fragilis suppresses seizures by activating a gut-brain cholinergic signaling pathway mediated via the vagus nerve, with clinical relevance in pediatric refractory epilepsy. Their integrative approach uncovers a mechanistic link between microbiota composition and neural excitability, advancing microbiota-based interventions for neurological disorders.

• STING agonist-1: Transforming B Cell Activation Workflows

  2026-07-01

  STING agonist-1 enables precise, reproducible activation of the STING pathway for dissecting innate immunity and B cell-driven anti-tumor responses. This guide demystifies its integration in advanced immunology workflows with protocol details and troubleshooting strategies.

• GANT61 in Tumor Microenvironment Remodeling: From GLI Inhibi

  2026-07-01

  Explore how GANT61, a potent GLI inhibitor, enables mechanistic studies of tumor immune evasion and immunotherapy resistance by targeting GLI1/2-driven microenvironmental remodeling. Uncover actionable insights for cancer research that go beyond protocol optimization and delve into translational relevance.

• EdU Imaging Kits (Cy5): Precise S-Phase DNA Synthesis Detect

  2026-06-30

  EdU Imaging Kits (Cy5) enable high-sensitivity, morphology-preserving quantification of cell proliferation through advanced click chemistry, outperforming traditional BrdU-based assays. Their robust workflow integrates seamlessly with fluorescence microscopy and flow cytometry, making them ideal for genotoxicity, pharmacodynamic, and cell cycle studies.

• Omeprazole (A2845): Practical Protocols for Gastric Acid Res

  2026-06-30

  Omeprazole (SKU A2845) is a potent H+,K+-ATPase inhibitor designed for research applications investigating gastric acid secretion and antiulcer activity. It is not suitable for diagnostic or therapeutic use, and workflows should adhere to product-specific stability and solubility requirements to ensure reproducibility in preclinical models.

• Salvianolic Acid B Inhibits LH2 to Counter Pulmonary Fibrosi

  2026-06-29

  The reference study characterizes Salvianolic acid B as a potent inhibitor of lysyl hydroxylase 2 (LH2), directly reducing pathological collagen cross-linking and extracellular matrix stiffening in pulmonary fibrosis models. These findings illuminate a targeted, natural product–based strategy for modulating fibrotic remodeling, with practical implications for research on antifibrotic interventions.

• Bufalin: Mechanistic Advances and Strategic Impact for TNBC

  2026-06-29

  Bufalin, a cardiotonic steroid, has emerged as a transformative agent in translational oncology, particularly for triple-negative breast cancer (TNBC) and hepatocellular carcinoma. This article synthesizes the latest mechanistic insights, experimental protocols, and strategic guidance for researchers leveraging Bufalin’s unique molecular glue and apoptosis-inducing properties. Drawing on recent breakthroughs in STK33 targeting and AP-1 pathway activation, we explore how high-purity Bufalin from APExBIO empowers advanced study designs, reproducibility, and translational relevance beyond conventional compound pages.

• Doxorubicin Hydrochloride: Mechanistic Insights and Translat

  2026-06-28

  This thought-leadership article explores the dual utility of Doxorubicin (Adriamycin) HCl as a gold-standard tool for cancer chemotherapy research and a sophisticated model for cardiotoxicity. It synthesizes recent mechanistic advances—including the ATF4/H2S axis in cardioprotection—with actionable protocol guidance, comparative analysis, and a forward-looking perspective for translational researchers. Key evidence from cutting-edge studies is highlighted and contextualized within APExBIO’s Doxorubicin offering.

• SMPD4, Sphingolipid Metabolism, and Primary Cilia in Brain D

  2026-06-27

  A recent study unravels how SMPD4-driven sphingolipid metabolism is crucial for the development of primary cilia and neural structures in the brain. By dissecting genetic, cellular, and in vivo mechanisms, the authors link ceramide synthesis to neural progenitor survival and ciliary integrity, providing a new mechanistic framework for understanding rare neurodevelopmental disorders.

• 5-Azacytidine: Precision Epigenetic Modulation in Cancer Mod

  2026-06-26

  This thought-leadership article explores the dual mechanistic and translational power of 5-Azacytidine (5-AzaC) as a DNA methyltransferase inhibitor in cancer research. It synthesizes new mechanistic insights, strategic guidance for experimentalists, and the evolving context of combination therapies in multiple myeloma and leukemia, while providing protocol parameters and actionable recommendations for translational researchers.

• KCNE4 Modulation Alters Kv1.3 Blocker Pharmacology in Leukoc

  2026-06-26

  This study demonstrates how the auxiliary subunit KCNE4 modulates the pharmacological profile of the Kv1.3 potassium channel in immune cells. By selectively altering the inhibition kinetics of intracellular blockers such as Psora 4, the research highlights the significance of channel composition for effective immunomodulatory strategies targeting effector memory T cells.

• Fenofibrate: PPARα Agonist Workflows for Liver & Cancer Rese

  2026-06-25

  Fenofibrate empowers researchers to dissect PPARα and YAP signaling in both lipid metabolism and cancer biology models. This article delivers actionable protocols, troubleshooting tips, and context from a landmark study demonstrating age-independent hepatic responses, positioning Fenofibrate as a versatile tool for robust, reproducible experiments.

459 records 13/31 page Previous Next First page 上5页 1112131415 下5页 Last page